Skip to main content

Cameron Robert Wolfe

Professor of Medicine
Medicine, Infectious Diseases
Duke Box 102359, Division of Infectious Diseases, DUMC, Durham, NC 27710
Room 159 Hanes House, Trent Drive, Durham, NC 27710

Selected Grants


CISA 2023 Clinical Contributing Task 1

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

CISA 2023 Clinical Contributing Task 2

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

Collaboratory of AIDS Researchers for Eradication (CARE)

ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2025

CISA 2023 Clinical Contributing Task 1

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

CISA 2023 Clinical Contributing Task 2

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

Collaboratory of AIDS Researchers for Eradication (CARE)

ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2025

Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients

ResearchPrincipal Investigator · Awarded by Vanderbilt University Medical Center · 2022 - 2024

ACTG-STOMP A5418

Clinical TrialPrincipal Investigator · Awarded by University of California - Los Angeles · 2022 - 2023

CISA Consult 2022 Contributing Task 3

Clinical TrialInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023

Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2023

DAS181-3-01

Clinical TrialPrincipal Investigator · Awarded by Ansun BioPharma, Inc · 2019 - 2023

CISA 07 Adult RCT COVID-19 Vaccination (Lead)

ResearchSafety Coordinator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022

ACTIV1: Master Protocol for Immune Modulars: Remdisivir in COVID 19 patients

Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2020 - 2022

CARE Focus 1: Latency Biomarker Project

ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2022

Ph IIa, randomized, double blind placebo controlled trial of EIDD-2801 to eliminate COVID Viral RNA detection

Clinical TrialPrincipal Investigator · Awarded by Ridgeback Biotherapeutics LP · 2020 - 2022

Adaptive COVID-19 Treatment Trial (ACTT)

ResearchPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2020 - 2021

CMV Quant Assay

Clinical TrialPrincipal Investigator · Awarded by Hologic, Inc. · 2019 - 2021

Phase III, Remdesivir (GS-5734) in severe COVID-19 participants

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2021

Phase III study of Remdesivir in Moderate COVID-19 patients

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2021

CARE Duke-UNC Latency Biomarker Supplement Year 2

ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2018

Insight Flu Studies, M59-DU-074-1101-3 Task Order 4

ResearchInvestigator · Awarded by Institute for Clinical Research, Inc. · 2014 - 2018

Duke Continuing Medical Educational Program: CHEST

ConferencePrincipal Investigator · Awarded by American College of Chest Physicians · 2018 - 2018

CRB-SSS-S-16-004809 - Protocol IRC 003- TO#Q7

Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2015 - 2017

Task Order CRB-SSS-S-13-003314 - Protocol IRC 003

Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2013 - 2015

Task Order CRB-SSS-S-13-003283 - Protocol IRC004

Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2013 - 2014

External Relationships


  • Atea Pharmaceuticals
  • Biogen
  • Jansen Pharmaceuticals
  • adamis

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.